 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] AI healthcare company Lunit said today that it has signed a contract to acquire Volpara, a company that supplies AI solutions to more than 2,000 medical institutions in the U.S.
The goal is to approach 'cancer conquest through AI' through business and financial synergies through acquisition.
Today, Lunit signed a contract to acquire AI company 'Volpara Health Technology (Volpara Health Technologie)' for about 2,525 billion won.
Lunit said it considered Volpara's vast amount of medical data and its position in the U.S., and decided on the acquisition because of the great product synergy between the two companies.
AI is advantageous with more data to learn. Volpara has more than 100 million medical data. In addition, Volpara supplies products to more than 2,000 medical institutions in 48 states in the United States.
With the use of Volpara data, Lunit has advanced the development of 'AI-based accuracy of 99% or more cancer screening' technology and has made it easier to enter the United States.
CEO Seo also added that this will enable Lunit to achieve 100 billion won in sales by 2025.
He said he would consider external procurement to raise more than 200 billion won in acquisition funds.
On the other hand, the completion of the acquisition requires approval from more than 75% of Volpara shareholders, which will take about three to six months.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
